PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Vieira-Silva, S.* ; Falony, G.* ; Belda, E.* ; Nielsen, T.* ; Aron-Wisnewsky, J.* ; Chakaroun, R.* ; Forslund, S.K.* ; Assmann, K.* ; Valles-Colomer, M.* ; Nguyen, T.T.D.* ; Proost, S.* ; Prifti, E.* ; Tremaroli, V.* ; Pons, N.* ; Le Chatelier, E.* ; Andreelli, F.* ; Bastard, J.P.* ; Coelho, L.P.* ; Galleron, N.* ; Hansen, T.H.* ; Hulot, J.S.* ; Lewinter, C.* ; Pedersen, H.K.* ; Quinquis, B.* ; Rouault, C.* ; Roume, H.* ; Salem, J.E.* ; Søndertoft, N.B.* ; Touch, S.* ; Dumas, M.E.* ; Ehrlich, S.D.* ; Galan, P.* ; Gøtze, J.P.* ; Hansen, T.* ; Holst, J.J.* ; Køber, L.* ; Letunic, I.* ; Nielsen, J.* ; Oppert, J.M.* ; Stumvoll, M. ; Vestergaard, H.* ; Zucker, J.D.* ; Bork, P.* ; Pedersen, O.* ; Bäckhed, F.* ; Clément, K.* ; Raes, J.*

Statin therapy is associated with lower prevalence of gut microbiota dysbiosis.

Nature 581, 310-315 (2020)
Postprint Forschungsdaten DOI PMC
Open Access Green
Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent Flemish Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
42.778
9.199
54
97
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0028-0836
e-ISSN 1476-4687
Zeitschrift Nature
Quellenangaben Band: 581, Heft: 7808, Seiten: 310-315 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-506500-001
Förderungen NIHR Imperial Biomedical Research Centre
Novo Nordisk Foundation
FWO EOS program
Rega Institute for Medical Research
VIB Grand Challenges programme, KU Leuven
Research Foundation Flanders (FWO Vlaanderen)
French National Agency of Research (ANR)
European Union's Seventh Framework Programme for research, technological development and demonstration
DOI 10.1038/s41586-020-2269-x
WOS ID WOS:000618867700001
Scopus ID 85085123633
PubMed ID 32433607
Erfassungsdatum 2020-05-28
[➜Korrektur melden]